Plain-English translation of NCT07094516 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it's safe and effective for people in the early stages of Alzheimer's disease. Researchers want to learn whether the treatment can help preserve memory and thinking abilities, support daily activities, and slow changes in the brain. You would receive the medication as an infusion (through an IV) and be monitored for 72 weeks.
Alzheimer's disease damages memory and thinking abilities over time, and there are limited treatment options for people in the early stages. This trial is exploring whether this new medication might help slow the disease's progression and protect brain function.
You likely qualify if…
You likely don't qualify if…
You would visit the study clinic regularly over 72 weeks (about 1.5 years) to receive infusions of either the new medication or a placebo through an IV. During your visits, researchers would assess your memory and thinking abilities, check how well you're managing daily activities, and perform brain imaging to track changes. You'll need to bring a study partner to appointments, and the research team will monitor your safety throughout the trial.
AI-generated summary from trial data · Jul 5, 2026 · Not medical advice
United States